Trials / Completed
CompletedNCT00051974
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
A Randomized, Multicenter, Open-Label, Phase 2 Study of VELCADE Alone or VELCADE Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (planned)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.
Detailed description
In this study, patients with non-small cell lung cancer that is no longer responding to standard medical treatment with another anti-cancer drug will be randomly chosen to receive treatment with VELCADE alone or VELCADE in combination with docetaxel. Patients have almost equal chance of getting into either of the two treatment arms listed above.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VELCADE™ (bortezomib) for Injection (formerly PS-341) |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2004-09-01
- First posted
- 2003-01-22
- Last updated
- 2008-02-11
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00051974. Inclusion in this directory is not an endorsement.